Regeneron's Livsayis Receives FDA Approval for Generalized Myasthenia Gravis, Offering Quarterly Dosing
Rapid Read

Regeneron's Livsayis Receives FDA Approval for Generalized Myasthenia Gravis, Offering Quarterly Dosing

What's Happening? Regeneron has received FDA approval for Livsayis (cemdisiran), an RNA-based therapy for adults with AChR antibody-positive generalized myasthenia gravis (gMG). This marks Regeneron's entry into the neurology category and is the first siRNA-based therapy for gMG. Livsayis is designe
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.